StudyFinder

A PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF RO7790121 IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Status: Recruiting

The purpose of this study is to learn about the efficacy and safety of RO7790121, which is a new medication being developed to treat people who have moderate to severe atopic dermatitis (AD). Participants will receive either the new medication or a placebo (doesn't contain any medicine) and the results will be compared. The total time of study treatment for an individual will be approximately 30 weeks.

I'm interested

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• Diagnosis of Atopic Dermatitis
Exclusion Criteria:

• Prior or current treatment with any approved or investigational biologics
Conditions:

Dermatology (Skin, Hair & Nails)

Keywords:

Atopic Dermatitis, Clinics and Surgery Center (CSC)

Study Contact: Jaime Nugent - speck007@umn.edu
Principal Investigator: Paul Bigliardi
Phase: PHASE2
IRB Number: STUDY00025347
See this study on ClinicalTrials.gov

Back